Topic

Feliza Mirasol is the science editor for 

Articles

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.

Genentech Licenses Sangamo Therapeutics’ Epigenetic Regulation and Capsid Technologies in Nearly $2 Billion Deal for Genomics Medicines

Under the license agreement, Andelyin Biosciences will expand its AAV Curator Platform by including MyoAAV plasmids developed by Broad Institute of MIT and Harvard.

Andelyn Biosciences Inks License Agreement with Broad Institute of MIT to Expand AAV Platform Offering

With this acquisition, AbbVie gains Cerevel’s clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric disorders, migraine, and Parkinson's disease.

AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline

Under the expanded agreement, Univercells and University of Pennsylvania will evaluate certain bioreactors for scalable gene therapy production.

Univercells Expands Collaboration with University of Pennsylvania for Gene Therapy Manufacturing

Pluri’s newly launched CDMO business will manufacture two novel cell therapy product candidates for Kadimastem.

Pluri’s CDMO Business to Manufacture Cell Therapy Candidates from Kadimastem

The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.

AstraZeneca Strengthens Rare Disease Portfolio with Amolyt Pharma Acquisition

The acquisition of EyeBio adds a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration to Merck’s pipeline. 

Merck Completes EyeBio Acquisition, Strengthens Eye Disease Portfolio

The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.

Deals, Development and Manufacturing